Comparing the Safety and Efficacy of BOL-303259-X Ophthalmic Solution With Timolol Maleate Ophthalmic Solution in Subjects With Open-Angle Glaucoma or Ocular Hypertension

Inclusion Criteria:

• Participants must have a diagnosis of OAG (including pigmentary or pseudoexfoliative)or OHT in 1 or both eyes.

• Participants must meet the following IOP requirements at Visit 3

• mean/median IOP ≥ 24 mmHg at a minimum of 2 time points in the same eye

• IOP ≤ 36 mmHg at all 3 measurement time points in both eyes.

• Participants with a best-corrected visual acuity (BCVA), using the Early Treatment ofDiabetic Retinopathy Study (ETDRS) protocol, of +0.7 logMAR units (Snellen equivalentof approximately 20/100) or better in either eye.

Exclusion Criteria:

• Participants with known hypersensitivity or contraindications to latanoprost, NOtreatment, timolol maleate, other beta-adrenergic receptor antagonists or any of theingredients in the study drugs.

• Participants with a central corneal thickness greater than 600 μm in either eye.

• Participants with advanced glaucoma and participants with a cup/disc ratio greaterthan 0.8 or a history of split fixation, or a field loss threatening fixation ineither eye.

• Participants who do not have an intact posterior capsule in either eye .

• Participants with aphakia in either eye.

• Participants with previous or active corneal disease in either eye.

• Participants with current or a history of severe dry eye in either eye.

• Participants with current or a history of optic disc hemorrhage in either eye.

• Participants with current or a history of central/branch retinal vein or arteryocclusion in either eye.

• Participants with current or a history of macular edema in either eye.

• Participants with very narrow angles (3 quadrants with less than Grade 2 according toShaffer's anterior chamber angle grading system) and participants with angleclosure,congenital, and secondary glaucoma, and participants with history of angleclosure in either eye.

• Participants with a diagnosis of a clinically significant or progressive retinaldisease in either eye.

• Participants with any intraocular infection or inflammation in either eye within 3months(90 days) prior to Visit 1 (Screening).

• Participants with a history of ocular laser surgery in either eye within the 3months(90 days) prior to Visit 1 (Screening).

• Participants with a history of incisional ocular surgery or severe trauma in eithereye within 3 months (90 days) prior to Visit 1 (Screening).